Trial intelligence / Profile preview

KEYMAKER-U03 Substudy 03B: Immune and Targeted Combination Therapies in Second-Line Metastatic RCC

NCT04626518Phase 2Completed

Sponsor: Merck & Co.
Start: Dec 2020
Primary completion: Jul 2026
Modality: Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
Countries: 13

Overview

Phase 2, randomised, open-label trial of pembrolizumab, quavonlimab, favezelimab, mk-4830, belzutifan and 1 more in clear cell renal cell carcinoma (ccRCC) (6 arms), sponsored by Merck & Co. Primary endpoints: Dose-Limiting Toxicities at 21 days, Adverse Events at 56 months and 2 more. Started Dec 2020; status: completed.

Drugs

pembrolizumabquavonlimabfavezelimabmk-4830belzutifan

Conditions

clear cell renal cell carcinoma (ccRCC)

Beyond the preview

Go deeper on NCT04626518.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT04626518.